期刊文献+

低氧微环境对人肺癌细胞上皮间充质转化及迁移侵袭能力的影响 被引量:3

The Influence of Hypoxia Microenvironment on Metastasis Induced by Epithelial-Mesenchymal Transition of Human Lung Adenocarcinoma
原文传递
导出
摘要 目的探讨低氧微环境对肺癌细胞H460上皮间充质转化的影响。方法常氧和低氧(1%)培养人肺腺癌细胞系H460,分别用显微镜观察细胞形态的变化,采用Western blot检测上皮间充质转化标志物E-cadherin和Vimentin蛋白水平的变化,通过Transwell迁移和侵袭实验观察细胞迁移和侵袭能力的改变。结果常氧组的H460细胞呈不规则的多边形,而低氧组细胞出现纺锤形改变,部分细胞变得更加瘦长。与常氧组比较,低氧组的上皮标志蛋白E-cadherin表达下调,而间质标志蛋白Vimentin增加;低氧微环境使细胞的迁移和侵袭能力都得到了增强。结论低氧微环境促进了肺癌细胞的上皮间充质转化,并增强了其转移能力。 Objective To investigate the influence of hypoxia on pro-metastasis induced by epithelial-mesenchymal transition (EMT) of human lung adenocarcinoma. Methods The human lung cancer cell line H460 was cultured in hypoxic condition and the morphologic changes of the cells were observed under the microscope. The EMT-related markers including E-cadherin and vimentin were detected by Western blot. Transwell migration assay and transwell invasion assay were employed to detect the migratory and invasive activity of cancer cells. Results Hypoxic induced morphological changes were consistent with the mesenchymat phenotype, such as an elongated fibroblastic morphology, and conversion from a tightly packed epithelial cobblestone pattern to a loosely packed scattered phenotype. Compared with the control group, hypoxic attenuated the quantity of E-cadhenrin, but increased vimentin, which resulted in promotion of migration and invasion of H460. Conclusion Hypoxia induces EMT in H460 and enhances the invasive and migratory abilities of lung cancer cells.
出处 《中国呼吸与危重监护杂志》 CAS 北大核心 2016年第5期465-469,共5页 Chinese Journal of Respiratory and Critical Care Medicine
基金 国家自然科学基金(编号:81470228 81270087 81500023) 广东省医学科研基金(编号:A2015386) 广东省自然科学基金(编号:2014A030310325)
关键词 肺癌 低氧 上皮间充质转化 迁移 侵袭 Lung cancer Hypoxic Epithelial-mesenchymal transition Migration Invasion
  • 相关文献

参考文献15

  • 1Brock A, Krause S, Ingber DE. Control of cancer formation by intrinsic genetic noise and mieroenvironmental cues. Nat Rev Cancer, 2015, 15:499-509.
  • 2Nieto MA. The ins and outs of the epithelial to mesenehymal transition in health and disease. Annu Rev Cell Dev Biol, 2011, 27 : 347-376.
  • 3Kise K, Kinugasa-Katayama Y, Takakura N. Tumor mieroenvironment for cancer stem cells. Adv Drug Deliv Rev, 2016, 99:197-205.
  • 4Bedogni B, Welford SM, Cassarino DS, et al. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell, 2005, 8:443-454.
  • 5Ballas LK, Hu BR, Quinn DI. Chromoplexy and hypoxic mieroenvironment drives prostate cancer. Lancet Oncol, 2014, 15:1419-1421.
  • 6Higgins DF, Kimura K, Bernhardt WM, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to- mesenehymal transition. J Clin Invest, 2007, 117:3810-3820.
  • 7Bartis D, Mise N, Mahida RY, et al. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important? Thorax, 2014, 69: 760-765.
  • 8Rho JK, Choi Y J, Lee JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer, 2009, 63:219-226.
  • 9Shintani Y, Okimura A, Sato K, et al. Epithelial to mesenehymal transition is a determinant of sensitivity to ehemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg, 2011, 92: 1794- 1804.
  • 10Nieolini A, Ferrari P, Fini M, et al. Chemoresistanee to paelitaxel induces epithelial mesenehymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oneol, 2007, 31 : 277-283.

二级参考文献38

  • 1杨柳青,施毅,秦叔逵,钱军,韩宝惠,潘良熹,马胜林,李恩孝,蔡光蓉,李园,于国华,杨俊兰,王华庆,储大同.洛铂联合长春瑞滨治疗晚期非小细胞肺癌的临床研究[J].临床肿瘤学杂志,2006,11(12):890-894. 被引量:39
  • 2American Cancer Society. Cancer Facts & Figures 2004. Atlanta, GA : American Cancer Society,2004, 22-23.
  • 3Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin,2000,50:7-33.
  • 4Jemal A, Murray T, Samuel A, et al. Cancer statistics,2003. CA Cancer J Clin,2003 ,53 :5-26.
  • 5Landis SH, Murray T, Bolden S, et al. Cancer statistics,1999. CA Cancer J Clin, 1999,49:8-31.
  • 6Mountain CF. International staging system for lung cancer. In : Pass H, Mitchell J, Johnson D, Turrisi A, Minna J, eds. Lung cancer, second. Philadelphia : Lippincott Wiliams Wilkin ,2000,591 -601.
  • 7Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ, 1995, 311: 899-909.
  • 8Gandara DR, Crowley J, Livingston RB, et al, Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol, 1993,11 : 873 -878.
  • 9Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol, 2004,22:3852- 3859.
  • 10Ardizzoni A, Boni L, Tiseo M, et al. Cisplatinversus carboplatin-based chemotherapy in first-line treatment of advanced non-small- cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 2007, 99 : 847-857.

共引文献3

同被引文献24

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部